MyCTC chip: microfluidic-based drug screen with patient-derived tumour cells from liquid biopsies.

ABSTRACT: Cancer patients with advanced disease are characterized by intrinsic challenges in predicting drug response patterns, often leading to ineffective treatment. Current clinical practice for treatment decision-making is commonly based on primary or secondary tumour biopsies, yet when disease progression accelerates, tissue biopsies are not performed on a regular basis. It is in this context that liquid biopsies may offer a unique window to uncover key vulnerabilities, providing valuable information about previously underappreciated treatment opportunities. Here, we present MyCTC chip, a novel microfluidic device enabling the isolation, culture and drug susceptibility testing of cancer cells derived from liquid biopsies. Cancer cell capture is achieved through a label-free, antigen-agnostic en

SUBMITTER: Schwab FD 

PROVIDER: S-EPMC9763115 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature